August 7, 2019
MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) finally vaulted to the top spot in IQVIA’s quarterly drug sales ranking in Japan, notching up 31,578 million yen in April-June this year on an NHI price basis, up 64.1% year on year. The drug...read more